TrialJAMA oncology2019

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Paolo A Ascierto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.